G1 Therapeutics’ approach to cancer does not kill tumors. Instead, the biotech’s drug, trilaciclib, protects bone marrow from the damaging effects of chemotherapy, reducing the duration and severity ...
Just as we receive news of the demise of our good old faithful T-Mobile G1, I also have news of some testing I’ve been doing while I had the Samsung Vibrant here. The tests are all run on the T-Mobile ...
RESTON, Va.--(BUSINESS WIRE)--ICO Global Communications (Holdings) Limited (ICO) (NASDAQ:ICOG) today announced that ICO G1 satellite In Orbit Testing (IOT) and testing of the innovative Ground Based ...
No sooner had we taken our UK T-Mobile G1 out of its box when someone shouted out, "Does it have 3G then?" It does indeed have 3G, but what's more interesting is that during testing we found out that ...
G1 Therapeutics’ cancer drug trilaciclib has failed to beat placebo against multiple efficacy measures in phase 2. Trilaciclib performed well against its neutropenia-related primary endpoints but fell ...
The RTP drug developer says development of the drug has gone "smoothly." In May, Mark Velleca of G1 Therapeutics promised the world would hear more from him. On Wednesday, he made that happen when G1 ...
LEESBURG, Va. — The National Institute for Automotive Service Excellence (ASE) is offering an online option for those taking the automobile maintenance and light repair technician (G1) certification ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback